

## OUR COMPANY

Boehringer Ingelheim is one of the world's 20 leading pharmaceutical companies.



Founded in 1885 in Ingelheim and family-owned to this day



51,000 employees worldwide

### FOCUS ON



Human Pharma



Animal Health



Biopharmaceutical Contract Manufacturing

## DIVERSITY & INCLUSION DRIVE INNOVATION

**48%**  
women\*

**38%**  
female leaders\*

Innovation / growth

**41%**  
GENERATION Y (1981–2000)\*



**13%**  
BABY BOOMERS (1946–1964)\*

**46%**  
GENERATION X (1965–1980)\*

\*Boehringer Ingelheim worldwide, 2019

DIVERSITY IS NOT ONLY ABOUT



Minorities



Individuals



Compliance / ethics



Balance



Team composition



Innovation / growth

DIVERSITY IS ALSO ABOUT

## SUCCESSFUL BUSINESSES

### HUMAN PHARMA

**13,961 million EUR**  
NET SALES  
in 2019

### FOCUS ON



Respiratory diseases



Cardiovascular and metabolic diseases



Central nervous system + immunology



Oncology

### ANIMAL HEALTH

**4,035 million EUR**  
NET SALES  
in 2019



GLOBAL PLAYER

### SHARE

**61%**  
COMPANION ANIMALS



**39%**  
LIVESTOCK



**55%**  
PETS



**14%**  
CATTLE



**13%**  
SWINE



**10%**  
POULTRY



**6%**  
EQUINE

**2%**  
VPH\*

\*Veterinary Public Health (VPH)

### BIOPHARMACEUTICAL CONTRACT MANUFACTURING

Boehringer Ingelheim is a world-leading contract manufacturer of biopharmaceuticals.

**786 million EUR**  
NET SALES  
in 2019

We operate  
**1**

GLOBAL NETWORK



of biopharmaceutical production sites in Europe, the USA and Asia

We are a pioneer in biopharmaceuticals WITH OVER  
**35**  
YEARS of experience

We have manufactured MORE THAN  
**35**

BIOPHARMACEUTICALS for global markets

## SUSTAINABLE ECONOMIC & SCIENTIFIC ACTIVITY

### ECONOMIC SUCCESS (2019)

**18,997 million EUR**  
NET SALES

**19.9%**  
RETURN ON NET SALES

### AMERICAS



**8,830 million EUR**

### EUROPE



**5,689 million EUR**

### ASIA / AUSTRALIA / AFRICA (AAA)



**4,478 million EUR**

### RESEARCH & DEVELOPMENT

**3,042 million EUR**

Human Pharma expenses in research & development in 2019



Focus on research therapeutic areas



Scientific platforms



Research Beyond Borders

**21.8%**  
of Human Pharma net sales 2019

## SOCIAL RESPONSIBILITY

### MAKING MORE HEALTH



ASHOKA

Making More Health is a global initiative by Boehringer Ingelheim in cooperation with Ashoka, a non-governmental organisation. Its aim is to improve healthcare for people worldwide.

MORE THAN  
**100**

social entrepreneurs in over 30 countries received support since 2010

APPROX.  
**6,000**

Boehringer Ingelheim employees worldwide are involved in the initiative